Full Press Release Details
Galapagos Publishes 2024 Annual Report and
Announces Annual Shareholders Meeting
Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual
report for the financial year 2024 and announces its Annual Shareholders Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company.
The annual report for the financial year 2024, including a review of figures and performance, is available online at
https://www.glpg.com/financial-reports and can also be downloaded as PDF. The annual 2024 Form 20-F filing with the SEC is available at www.sec.gov/edgar.
Galapagos has the honor to invite its shareholders, holders of subscription rights, Board members, and statutory auditor to its Annual (ordinary)
Shareholders Meeting that will be held on Tuesday April 29, 2025 at 14:00 CET at the Company s registered office.
The items on the agenda
of the AGM include, amongst other items: (i) the appointment of Mr. Oleg Nodelman as Non-Executive Non-Independent Director, and (ii) the confirmation and
appointment of the statutory auditor with respect to the assurance of the Corporate Sustainability Reporting Directive 2022/2464/EU (CSRD) sustainability reporting.
The proposed separation of Galapagos into two publicly traded entities is not included on the agenda of this AGM. An Extraordinary Shareholders Meeting
in relation to this matter is expected to be convened mid-2025.
In order to be admitted to the AGM to be held on
April 29, 2025, the holders of securities issued by the Company must comply with article 7:134 of the Belgian Code of Companies and Associations and article 23 of the Company s Articles of Association, and fulfil the formalities described
in the convening notice. The convening notice and other documents related to this AGM, including the biography of Mr. Oleg Nodelman, can be consulted on our website at www.glpg.com/shareholders-meetings.
We are a biotechnology company with
operations in Europe and the U.S. dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology,
and collaborative approaches to create a deep pipeline of best-in-class medicines. With capabilities from lab to patient, including a decentralized cell therapy
manufacturing platform, we are committed to challenging the status quo and delivering results for our patients, employees, and shareholders. Our goal is not just to meet current medical needs but to anticipate and shape the future of healthcare,
For further information, please contact:
Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These statements speak only as of
the date of publication of this release. We expressly disclaim any obligation to update any forward-looking statements in this release, unless specifically required by law or regulation.
The contents of our website, including the
annual report for the financial year 2024, and any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.